Page 1 2019 2019
Total Page:16
File Type:pdf, Size:1020Kb
Ѯᢊϛॳᚂᇬ Ҭȁᓃ 䫔 1 ⌟ 䫔 3㛇 2019 ⸜ 12 㚰 ࡾġġЕ 2019⎘䀋儎ᷕ桐⬠㚫朆䵕Ṿ␥K㊖㈿∹⎋㚵㈿ↅ埨∹䓐㕤⽫举䵕栓≽か侭ᷕ桐 枸旚㱣䗪㊯⺽ 㜿晭⤪ˣ湫劙⹕ˣⲼ䘦曺ˣ哉≃↙ˣ挦剟厵ˣ悕㚠ⶮˣ⬳䡏⥵ˣ䵕ṩˣ ⽫举䵕栓≽枸旚ᷕ桐㱣䗪㊯⺽ℙ嬀⮷䳬.............................................................................. 143 ᆣġġ፣ ㈿ↅ埨∹䚠斄⿏儎↢埨䘬喍䈑㱣䗪 昛⿅㰅ˣ㜿㫋₨ˣ哉≃↙....................................................................................................... 185 2019⸜8㚰⊿⋨儎ᷕ桐暁㚰㚫Highlight 㜄叔列ˣ昛⎛䶗ˣ昛㝷暾....................................................................................................... 194 ijıIJĺԑѮᢊသϛॳᏰོᏰंଆོ 㚫嬘嬘䦳........................................................................................................................................... 204 ⸜㚫屜屻㺼嫃.................................................................................................................................. 212 ⃒䥨婾㔯䋶⼿䋶⎵╖..................................................................................................................... 213 ⃒䥨婾㔯䋶㐀天.............................................................................................................................. 214 ⡩⟙婾㔯㐀天.................................................................................................................................. 221 Formosan Journal of Stroke Volume 1, Issue 3, DEC 2019 Contents Guidelines 2019 Taiwan Stroke Society Guideline on the Use of Non-Vitamin K Antagonist Oral Anticoagulants for Prevention of Stroke in Patients with Atrial Fibrillation Ya-Ju Lin, Ying-Ting Huang, Pai-Ching Tsui, Li-Kai Tsai, Chih-Ping Chung, Shu-Fan Kuo, Pi-Shan Sung, Helen L. Po, Taiwan Stroke Society Guideline Consensus Group...................143 Review Articles Medication Treatment in Anticoagulant-Associated Intracerebral Hemorrhage Szu-Ju Chen, Shin-Yi Lin, Li-Kai Tsai..................................................................................... 185 Northern Taiwan Bimonthly Stroke Meeting Highlight Wanliang Du, Yu-Wei Chen, Po-Lin Chen............................................................................... 194 2019 Annual Meeting of Taiwan Stroke Society Meeting Programs......................................................................................................................... 204 Plenary Lecture.............................................................................................................................. 212 Excellent Paper Winners............................................................................................................. 213 Abstracts of Excellent Papers.................................................................................................... 214 Abstracts of Poster Papers.......................................................................................................... 221 ၗޟߝٱ౩ က୷࿎௲ᙴଣᆶߏ۪ᙴଣᖐՉǴ೭ࢂܭҁԃ11Д22-24Вܭ2019ԃѠတύ॥ԃஒ ځεࠠᏢೌࢲǶၸ۳Ǵတύ॥ԃନΑ2011ԃමӧᄆϯᖐՉǴޑᏢಃԛӧကᖐՉ ཀကᆶՅǴБय़ࢂတύڀᖐՉǴϞԃӧကᖐՉǴձޑдԃӧчǵύǵଯ ҞǶќБޑගϲύ॥ݯᕍࠔ፦ǵᕭλࠤໂৡຯࢂᏢޑǴӄय़זᡂϯࡐޑ॥ບᕍ ѬᙴଣᏢಞǶϞځԋ݀ǴॶளޑǴၸѐ൳ԃԖ࣬ӳزᙴৣॺӧύ॥ບᕍᆶࣴޑय़ࠄ ᆶߏයྣៈനཥЪ܄යບᘐᆶݯᕍǵ٥࡚܄ଣࡕࢬำǵ࡚ډҞ఼ᇂԾଣ௱ៈǵޑԃ ᔈҔǵՈਵ౽ନπբ֝ǴϣᆒߍǴॶள೭ΒǵޑፕǴΨхࡴΓπඵችӧύ॥ޑֹ ೭ᙴᏢᆶӧӦ॥Ǵᆃ၈߆ாኘϧᆿᖏୖуǶڙΟВӧကӳӳ٦ ᙣઔ εԋф Ѡတύ॥Ꮲ٣ߏ ལᗎ 2019ԃ11Д22В Welcome Message Dear Colleagues, The 2019 Taiwan Stroke Society (TSS) Annual Meeting will be held at Chiayi Christian Hospital and Chiayi Chang Gung Memorial Hospital from November 22th (Friday) to 24th (Sunday), 2019. This is the first large stroke academic event held in Chiayi. In the past, except for one TSS annual meeting held in Changhua in 2011, the other annual meetings were held in the Taipei, Taichung, and Kaohsiung cities. This year’s meeting in Chiayi has important features. The progress of stroke diagnosis and treatment is fast, and to narrow the gap between urban and rural areas in stroke management is important. Furthermore, excellent performance in stroke management and research by stroke specialists in Chiayi and Tainan is commendable. This meeting's program covers from pre-hospital emergency services, acute phase diagnosis and treatment, post-acute care and long- term care, as well as artificial intelligence in stroke applications, thrombectomy workshops, etc. It is worthwhile to enjoy this medical feast and local style in Chiayi. We sincerely anticipate your attendance. Sincerely yours President, Taiwan Stroke Society November 22, 2019 σོкৰޟၗ ӚՏᙴৣǵৎǵᏢޣϷӃ ໋᠙ ߆ୖу2019ԃѠတύ॥ᏢԃǴҁԛԃஒܭ2019ԃ11Д22ВԿ24Вܭကᖐ ΓϯᙴᕍϝԖࡑঁޑǴฅԶଞჹύ॥ੰΓޑݯᕍԖ࣬ӭޑՉǶӧၸѐ೭ԃǴύ॥ ոΚǶӧԜǴᙣж߄ԃᝢഢǴགᖴੇϣѦ܌ԖୖᆶޑᇯǶϞԃޑҞନΑхࡴύ॥ ࡕයϷߏයྣៈ܄ݯᕍǵ࡚܄ଣύ॥ᒣǵύ॥ቹႽᔠǵ࡚ډӵٯၸำǴֹޑៈྣ ୀෳᆶೀǵү՟ޑύ॥ёૈٰྍ܄ӵଞჹਵηٯЬᚒǴޑჴҔ׳ܭ၂ᆫข׳ॺךѦǴ ޑᙴᏢϐ҂ٰǶགᖴாܭॺΨ߃ΓπඵችᔈҔךບᘐǶԜѦǴޑࠠ߄ڂύ॥ᆶύ॥ό ԏᛘǶޑᆶ٠׆ఈாԖᅈᅈୖ ᡏ଼ந ٣ӵཀي ᙣઔ 2019ԃ11Д22В Dear friends and colleagues, Welcome to the 2019 Annual Meeting of Taiwan Stroke Society, which will take place in Chiayi on November 22 to 24, 2019. Over the past year, there have been many exciting advances in the treatment of stroke. However, we are way behind when it comes to delivering personalized medicine to patients with stroke. On behalf of the organizing committee, I would like to thank all guest speakers and moderators from overseas and all the attendees. The 2019 program includes the full continuum of stroke care such as prehospital stroke identification, imaging of stroke, acute treatment, post-acute and long-term care. Moreover, we try to organize a meeting to focus on more down-to- earth topics such as detection and management of embolic stroke of possible sources and diagnosis of stroke mimics and chameleons. We also take a glimpse into the future of artificial intelligence in medicine. Thank you for joining us for this event and we hope you enjoy this meeting. Sincerely yours, November 22, 2019 ϛॳႱ٩ݽᕛࡾЕޱᡊᆰᠬଢ଼ܘᏗՖᏘҢܻЖתᏘο݈תŌࡼڼࡾġġЕ ߨᆰт ᏗՖתᏘο݈תŌࡼڼijıIJĺѮᢊသϛॳᏰོߨᆰт ϛॳႱ٩ݽᕛࡾЕޱᡊᆰᠬଢ଼ܘᏘҢܻЖ 4ǵۇӵ1ǵम1ǵஞԭߙ1ǵጰΚഩ2ǵᗛ߀3ǵਜԁ1ǵֺᅸ݅ ᠼᆢႣٛύ॥ݯᕍࡰЇӅλಔ܊ഡᆢϘ1, 5ǵЈ ᙴଣઓࣽۺଭିइ 1 2Ѡεᙴଣઓᄤတύ॥ύЈ 3Ѡчᄪ҇ᕴᙴଣઓᙴᏢύЈઓϣࣽ 4ԋεᙴଣઓ ᙴଣတύ॥ύЈۺ5ଭିइ (ࠉȁȁِ 䓐㈿ↅ埨∹⮶农♜慵↢埨䘬桐晒⍲嗽伖烊(5 AFか侭䈡⭂冐⸲䉨㱩䘬嗽伖烉⊭⏓⸜攟侭ˣ㆟ ⽫举䵕栓≽(atrial fibrillation, AF)㗗⮶农 ⫽ˣら⿏儓䗌ˣ⎰Ἕ偅冇䕦䕭ˣ僶冇䕦䕭⍲≽ 仢埨⿏ᷕ桐㚨慵天䘬⌙晒⚈⫸ᷳᶨ炻ḇ㗗䚖⇵ 傰䱍䉨䠔⊾/栙埨䭉䊡䨬䫱烊(6) ἧ䓐NOACs 䘬 䁢㬊炻傥⣈㚱㓰ẍ⎋㚵㈿ↅ埨∹喍䈑ἄ䁢⇅䳂 㲐シḳ枭(⏓喍䈑ṌḺἄ䓐ˣ忚埴Ὕℍ⿏㩊㞍ㆾ 枸旚(primary prevention)䘬冐⸲䉨㱩ˤ娛䳘䘬 ㇳ埻䘬 喍冯ℵ䓐喍㗪㨇ᷳ⺢嬘䫱)ˣ⁛䴙⎋㚵 䚠斄㱣䗪㊯⺽㕤2012⸜䘤Ự炻᷎㕤2016⸜㚜 ㈿ↅ埨∹冯NOACsᷳ攻䘬廱㎃炻⍲䓐慷拗婌䘬 㕘ˤ㚱揹㕤⚃䧖朆䵕Ṿ␥K㊖㈿∹⎋㚵㈿ↅ埨 嗽䎮烊(7) ᶵ㖶⍇⚈ᷕ桐⍲⮵ᷕ桐か侭AF䘬” ∹(non-vitamin K antagonist oral anticoagulants, 㷔䫱ˤ NOACs)ᶲⶪẍἮ炻映临㚱䚠䔞⣂㕘䘬慓⬠⮎ 㛔㫉㊯⺽⮎嫱⺽䓐炻㟡㒂AHA/ACC/HRS 嫱屯㕁䘤堐炻㓭㚱㛔㫉㚜㕘ˤᷣ天㚜㕘⍇2016 ὅ⺢嬘ᷳ⻟⹎↮䁢Class IˣIIaˣIIbˣIII⍲ὅ嫱 ㊯⺽䫔⚃䪈䭨烉AFか侭㈿埨㞻㱣䗪ᷳ嫱㒂冯 㒂⑩岒↮䁢Level of Evidence (LOE) AˣB-Rˣ ⺢嬘炻冯䫔Ḽ䪈VKA (warfarin)冯NOACs䘬㭼 B-NRˣC-LDˣC-EOˤ 庫冯廱㎃悐↮ 墄⃭冯㓡⮓炻ᷣ柴⊭⏓ẍᶳ㔠 溆烉(1) 㖶䡢⭂佑䒋兄⿏冯朆䒋兄⿏⽫举䵕 IJįġġᛞጰܒᇄߨᛞጰܒłŇޱ Ꮧתޟ栓≽炻᷎ὅ䄏か侭檀Ỷ桐晒Ⰼ䳂(high /low risk ଽճॳᓎቹຟե burden)䘬姽Ộ䴎Ḱ㈿ↅ埨喍䈑⺢嬘烊(2) ⚃䧖 Ֆސ࡚ដ NOACs: dabigatran, rivaroxaban, apixaban and edoxaban 怑⭄∹慷䘬怠㑯冯⺢嬘烊(3) AFか侭 ⤪ỽ枸旚ℵᷕ桐(secondary stroke prevention)烉 IJįIJġġᛞጰܒᇄߨᛞጰܒłŇᅸဎϞᚄ ⊭⏓⿍⿏仢埨⿏ᷕ桐㗪䘬嗽伖ˣỽ㗪怑⎰攳⥳ ఼ ἧ䓐ㆾ䓐⚆⎋㚵㈿ↅ埨∹炻ẍ⍲劍㗗儎↢埨 ẍ⼨斄㕤AF⭡㖻忈ㆸ儎埨䭉㠿⠆⍲℞Ṿ ⼴炻ℵ䓐⎋㚵㈿ↅ埨∹䘬㗪㨇烊(4) AFか侭ἧ ℐ幓⿏㞻⠆ḳẞ炻⺢嬘ἧ䓐⎋㚵㈿ↅ埨∹Ἦ 忂妲ἄ侭烉䵕ṩ, 楔´䲨⾝慓昊儎ᷕ桐ᷕ⽫ E-mail: [email protected] DOI: 10.6318/FJS.201912_1(3).0001 143 ϛॳႱ٩ݽᕛࡾЕޱᡊᆰᠬଢ଼ܘᏗՖᏘҢܻЖתᏘο݈תŌࡼڼߨᆰт 枸旚䘬䚠斄䞼䨞炻䘮姣㖶䁢朆䒋兄⿏AF (non- ᷳ⇵妶婾䘬炻2010⸜㍸↢䘬CHA2DS2VASc valvular AF, NVAF)ˤ忁ᾳ⎵娆Ụ᷶㊯㗗ᶵ傥㚱 score (0-9)㭼CHADS2 score (0-6)炻昌Ḯ庫Ἓ䘬 ảỽ⽫冇䒋兄䚠斄⓷柴炻Ữ⮎晃冐⸲䉨㱩᷎朆 㞻⠆ḳẞ枸㷔ᷳ⢾炻㚜傥⋨↮↢䛇㬋䘬Ỷ桐晒 ⤪㬌炻⍵㖻忈ㆸ婌妋ˤ2016⸜㫸㳚⽫冇⬠㚫ᷳ か侭(CHA2DS2VASc score 0↮䘬桐晒䁢0.78%/ AF㱣䗪㊯⺽(ESC guideline for the management of Ṣ‒⸜炻⮵㭼CHADS2 score 0↮䘬桐晒䁢1.67%/ AF patients)ᷕ炻⌛ᶵℵἧ䓐Ⱦnon-valvular AFȿ Ṣ‒⸜) 6ˤ冒2016⸜⎬⚳䘬㱣䗪㊯⺽炻⊭㊔ 忁ᾳ⎵娆ˤ⛐⎬ᾳ䫔ᶱ㛇NOACs冐⸲娎槿䘬⍿ ESCˣCanadian guidelineˣ2018 ACCPˣNHFA 娎侭炻ṵ㚱役20%か侭⎰Ἕ㚱⎬⺷䒋兄⿏⽫冇 CSANZ䫱炻䘮⺢嬘ἧ䓐CHA2DS2VASc scoreἄ 䕭ㆾ㗗㚦 忶䒋兄ㆸ✳埻ㆾ㎃忶䓇䈑䒋兄炻⛐ 䁢➢㛔䘬姽Ộⶍ℟1-5, 7ˤ℞ᷕ⁛䴙ẍ1↮䁢ᷕ⹎ 忁ṃか侭䘬㫉↮㜸栗䣢NOACsṵᾅ㚱䚠䔞䘬㓰 桐晒䘬㤪⾝炻⛐ἧ䓐CHA2DS2-VASc score㗪暨 㝄冯⬱ℐ⿏炻ẍ⍵侴㗗ẌṢ㶟㵮䘬⎵䧙ˤ侴 天⮯⿏⇍⚈⫸䈡⇍㍸↢妶婾ˤ⛐㚨役䘬䞼䨞ᷕ ⼴2018 EHRAˣ2019 AHA/ACC/HRS㚜㕘䘬AF 䘤䎦炻晾䃞⤛⿏AFか侭㚱庫檀䘬ᷕ桐㭼䌯炻Ữ 㱣䗪㊯⺽炻悥ᶵℵἧ䓐non-valvular AF1-5ˤ䎦Ṳ ℞⮎忁桐晒㗗晐叿⸜䲨⡆≈(⯌℞㗗 ≥ 75㬚侭)ㆾ 䒋兄⿏AF (valvular AF)⮰㊯ᷕ⹎军慵⹎Ḵ⮾䒋 㗗⚈䁢⎰Ἕℑ䧖ẍᶲ䘬桐晒⚈⫸侴⡆≈䘬1, 6ˤ 䊡䨬(moderate to severe mitral stenosis炻⼰⎗傥 䔞⤛⿏AFか侭㰺㚱℞Ṿ䚠斄桐晒⚈⫸⬀⛐㗪 暨忚埴䒋兄ㇳ埻)⍲㨇㡘䒋兄(mechanical valve) (⤛⿏CHA2DS2VASc score 1↮)炻℞ᷕ桐桐晒冯 1-3 伖㎃侭 ˤ忁ṃか侭⺢嬘暨攟㛇ἧ䓐warfarin 䓟⿏(䓟⿏CHA2DS2VASc score 0↮)㗗ᶨ㧋䘬ˤ ᷎ᾅ㊩怑䔞䘬INRẍ㚱㓰枸旚埨䭉㞻⠆ˤ侴⮵ ⎗夳⤛⿏⎒傥䬿㗗AFか侭ᷕ桐桐晒䘬≈⻟⚈⫸ ℞ᷕ㨇㡘䒋兄伖㎃か侭(ᶵ⏓䓇䈑䒋兄ㆾ䒋兄 (risk modifier)ᶼ㗗冯⸜䲨䚠斄䘬(age-dependent) ㆸ⼊埻)䈡⇍⻟婧⺢嬘ἧ䓐VKA (warfarin)侴朆 侴朆䌐䩳䘬⌙晒⚈⫸2, 3, 6ˤẍ⛐㫸伶㱣䗪㊯ NOACsㇵ傥䡢ᾅ㚱㓰枸旚儎㠿⠆䘬䘤䓇炻㟡 ⺽ᷕ炻斄㕤姽Ộᷕ桐/ℐ幓⿏㞻⠆ḳẞ炻劍䓟⿏ 㒂RE-ALIGN trial (Randomized, Phase II Study CHA2DS2VASc score ≥ 2↮炻⤛⿏ ≥ 3↮炻夾䁢檀 to Evaluate the Safety and Pharmacokinetics of 桐晒烊䓟⿏ CHA2DS2VASc score 1↮炻⤛⿏2↮ Oral Dabigatran Etexilate in Patients After Heart 夾䁢ᷕ⹎桐晒1-3, 5ˤỮ㗗㟡㒂⎘䀋ᾅ屯㕁⹓䘬 8, 9 Valve Replacement)䘬䳸㝄栗䣢炻⛐ᷣ≽傰䒋ㆾ 䞼䨞 炻CHA2DS2VASc score 0-4䘬⎘䀋AFか侭 㗗Ḵ⮾䒋㨇㡘䒋兄伖㎃か侭ᷕἧ䓐dabigatran炻 䘤䓇ᷕ桐䘬㭼ἳ㖶栗檀㕤䐆℠䘬䘤䓇䌯炻䓂军 ℵᷕ桐⍲↢埨桐晒㖶栗檀㕤warfarin䳬ˤ侴 㗗CHA2DS2VASc score 0↮䘬⸜ᷕ桐䌯Ṏ⎗檀忼 rivaroxabanˣapixaban ẍ⍲edoxaban⯂䃉䚠斄䘬 1.1% (CHA2DS2VASc score 1侭䲬2.7%)炻⮵㕤⚳ 䞼䨞嫱㒂1ˤẍᶳ斄㕤NOACs䘬⺢嬘䘮㌺昌ᷕ慵 ṢAFᷕ桐枸旚喍䈑䘬怠㑯暨天㚜䧵㤝ヶ慵䘬侫 ⹎Ḵ⮾䒋䊡䨬⍲㨇㡘䒋兄伖㎃か侭ˤ ㄖˤ NOACs䚠斄冐⸲娎槿屯㕁栗䣢炻Ṇ㳚AF IJįijġłŇޱॳᓎቹޟຟե 㕷佌㭼朆Ṇ㳚㕷佌㚱㚜檀㭼ἳ䘬ᷕ桐/㞻⠆ḳẞ AFか侭桐晒Ⰼ䳂䘬姽Ộ㕡⺷炻ᶨ䚜㚱⼰⣂ 䘬桐晒炻ᶼἧ䓐warfarin↢埨ḳẞ㖶栗庫⣂9ˤ 䚠斄䘬䞼䨞冯䇕嬘炻昌ḮAF㛔幓⮶农䘬ⶎ⽫ 侴⮎晃䓐㕤⎘䀋/Ṇ㳚⛘⋨䘬ᾅ屯㕁⹓屯㕁栗 㒜⣏冯埨㳩忇䌯㓡嬲䓊䓇䘬㞻⫸⢾炻㚜⣂㗗AF 䣢9-11炻ᶵ䭉㗗⛐仢埨⿏ᷕ桐䘬枸旚ˣ慵⣏↢埨 か侭ⷠ⎰Ἕ㚱⣂慵ℙ䕭(⤪檀埨⡻ˣ䱾⯧䕭ˣ 䘬䘤䓇炻ㆾ㗗栙ℏ↢埨䘬㭼ἳ炻NOACs悥㖶栗 ⅈ⽫䕭ˣ⽫堘䪕䫱)炻ἧ⼿ᷕ桐桐晒⣏䁢⡆≈ ⃒㕤warfarinˤ 6ˤ⎬桐晒⚈⫸䘬⼙枧䦳⹎ᶵᶨ炻⛐2012/2016 憅⮵AFか侭姽Ộ℞ᷕ桐冯↢埨桐晒⼴炻⮵ ⸜䘬⎘䀋儎ᷕ桐⬠㚫㊯⺽ᷕ 忶妶婾ˤ婈⤪ 㕤㈿ↅ埨喍䈑怠㑯䘬䵄⎰⺢嬘⤪ᶳ1-4烉 144 ϛॳႱ٩ݽᕛࡾЕޱᡊᆰᠬଢ଼ܘᏗՖᏘҢܻЖתᏘο݈תŌࡼڼߨᆰт (1) CHA2DS2VASc score䓟⿏ ≥ 2↮ㆾ㗗⤛⿏ ≥ Evidence C)ˤ 3↮䘬AFか侭炻⺢嬘ἧ䓐⎋㚵㈿ↅ埨∹⊭ (8) ⽫㑚≽ (atrial flutter)か侭炻⺢嬘㭼䄏AF ㊔烉warfarinˣdabigatranˣrivaroxabanˣ か侭桐晒姽Ộ炻ἧ䓐⎋㚵㈿ↅ埨∹(Class I, apixabanˣedoxaban (Class I, Level of Level of Evidence C)ˤ Evidence A)ˤ (9) ⭂㛇慵㕘姽Ộ AFか侭ᷕ桐冯↢埨桐晒炻 (2) 昌Ḯᷕ军慵⹎Ḵ⮾䒋䊡䨬ㆾ㨇㡘䒋兄伖 ẍ慵㕘㩊夾⎋㚵㈿ↅ埨∹ᷳ⽭天冯怠㑯 ㎃ᷳAFか侭⢾炻℞ṾAFか侭⺢嬘⃒⃰ (Class I, Level of Evidence C)ˤ ἧ䓐NOACs (dabigatranˣrivaroxabanˣ (10) CHA2DS2VASc score䓟⿏1↮ㆾ⤛⿏2↮䘬 apixabanˣedoxaban) (Class I, Level of AFか侭炻ἧ䓐⎋㚵㈿ↅ埨∹枸旚ᷕ桐㞻 Evidence A)ˤ ⠆ḳẞ㗗⎰䎮䘬怠㑯(Class IIb, Level of (3) ⺢嬘ẍ CHA2DS2VASc scoreἄ䁢AFᷕ桐